ClinicalTrials.gg
CompletedNCT00344552Updated Nov 13, 2009

Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

A Phase 2 interventional study of Paclitaxel in Esophageal Cancer, sponsored by Bristol-Myers Squibb. Completed at 12 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2009-11-13.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
53
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies testing paclitaxel in Esophageal Neoplasms — 11 open to participants now, 18 under way, none of them phase 3. Paclitaxel · Esophageal Neoplasms.

Enrollment
30th of 74
53 · median 40
Started
2006
with 2 others
Phase 2
48 of 80
6 open now
Registered
26th of 80
by date
Lead sponsor
2 of 80
Bristol-Myers Squibb

Among the 80 studies testing paclitaxel in Esophageal Neoplasms, this one is the 30th largest by enrollment of the 74 interventional ones that give a count, is one of 3 that started in 2006, is one of 48 in phase 2, and was the 26th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

11 of the 80 studies testing paclitaxel in Esophageal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies testing paclitaxel in Esophageal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical research study is to learn if BMS-181339 can shrink or slow the growth of the cancer in patients with advanced or recurrent esophageal cancer. The safety of this treatment will also be studied.

03

Conditions studied

  • Esophageal Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have
  • Patients must have experienced on pervious chemotherapy regime
  • Men and Women, with the age 20 years or older
  • PS: 0-1

Exclusion criteria

Exclusion Criteria:

  • Patients with previous therapy with Taxanes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    1

    Drug: Paclitaxel

Interventions

  • Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over

    Also known as: Taxol

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Time frame: at the end of the study

  2. Safety

    Time frame: at the end of the study

Secondary outcomes

  1. Response duration

    Time frame: at the end of the study

  2. Time to progression (TTP)

    Time frame: at the end of the study

07

Study locations

12 sites
  • Local Institution
    Nagoya, Aichi 464-8681, Japan
  • Local Institution
    Kashiwa-Shi, Chiba 277-0882, Japan
  • Local Institution
    Sagamihara-Shi, Kanagawa 228-8520, Japan
  • Local Institution
    Osaka-Sayama City, Osaka 589-8511, Japan
  • Local Institution
    Suita-Shi, Osaka, Japan
  • Local Institution
    Takatsuki-Shi, Osaka 569-8686, Japan
  • Local Institution
    Sunto-Gun, Shizuoka 411-8777, Japan
  • Local Institution
    Utsunomiya, Tochigi 320-0834, Japan
  • Local Institution
    Chuo-Ku, Tokyo 104-0045, Japan
  • Local Institution
    Toshima-Ku, Tokyo 170-8455, Japan
  • Local Institution
    Osaka, Japan
  • Local Institution
    Saitama, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2006
First posted
Jun 27, 2006
Start
Jun 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Nov 13, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00344552
First posted
Jun 27, 2006
Start date
Jun 2006
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Nov 13, 2009

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion